The low-risk group had significantly higher infiltration of immune cells, which primarily have anti-tumor immune functions, and showed a higher sensitivity to ICIs therapy, possibly acting through the AL365361.1/hsa-miR-17-5p/NLRP3 axis. The gene discussed is NLRP3; the disease is neoplasm.